Get the Stockscreener App
4.88
7.22%
-0.38
After Hours:
5.26
0.38
+7.79%
Radiopharm Theranostics Ltd Adr stock is traded at $4.88, with a volume of 6,608.
It is down -7.22% in the last 24 hours and down -21.29% over the past month.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
See More
Previous Close:
$5.26
Open:
$5.24
24h Volume:
6,608
Relative Volume:
0.19
Market Cap:
$38.47M
Revenue:
$2.34M
Net Income/Loss:
$-24.85M
P/E Ratio:
-1.4067
EPS:
-3.4691
Net Cash Flow:
$-23.25M
1W Performance:
-7.49%
1M Performance:
-21.29%
6M Performance:
+17.59%
1Y Performance:
+0.00%
1-Day Range:
$4.85
$5.24
1-Week Range:
$4.7901
$5.435
52-Week Range:
$3.4962
$50.82
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Name
Radiopharm Theranostics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare RADX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
4.88 | 40.92M | 2.34M | -24.85M | -23.25M | -3.4691 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-25 | Initiated | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Stock (RADX) Latest News
Radiopharm (ASX:RAD, Nasdaq:RADX) to Showcase Oncology Pipeline at Deutsche Bank ADR Conference - Kalkine Media
Radiopharm Theranostics to Present at Deutsche Bank ADR Virtual Investor Conference - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Perspective Therapeutics (CATX) - The Globe and Mail
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Globe and Mail
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025 - The Manila Times
Radiopharm Theranostics Announces November AGM with Key Resolutions - MSN
Radiopharm Theranostics secures A$35 million in private placement - Investing.com India
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV) - The Globe and Mail
Radiopharm Theranostics Accelerates RAD202 Clinical Trial Following Positive Safety Review - MSN
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Radiopharm Theranostics Limited: Strategic Advancements and Financial Stability Support Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Radiopharm Theranostics Hosts Webinar Series on Radiopharmaceutical Therapies - MSN
Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating - TipRanks
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody By Investing.com - Investing.com India
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody - Investing.com
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) By Investing.com - Investing.com India
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) - Investing.com
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewswire Inc.
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board By Investing.com - Investing.com India
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board - Investing.com
Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Brookline Capital Management - Defense World
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital - Investing.com
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital By Investing.com - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Trading Up 1% – Here’s Why - Defense World
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and COMPASS Pathways (CMPS) - The Globe and Mail
Radiopharm signs supply agreement with Cyclotek for prostate cancer drug - Investing.com
Radiopharm wins FDA fast track for cancer imaging agent By Investing.com - Investing.com South Africa
Radiopharm wins FDA fast track for cancer imaging agent - Investing.com
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
radiopharm theranostics begins patient dosing in new trial - Investing.com
radiopharm theranostics begins patient dosing in new trial By Investing.com - Investing.com India
radiopharm theranostics shares preclinical data on new cancer therapy By Investing.com - Investing.com South Africa
radiopharm theranostics shares preclinical data on new cancer therapy - Investing.com
Radiopharm secures lutetium-177 supply agreement By Investing.com - Investing.com South Africa
Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM - TipRanks
Radiopharm secures lutetium-177 supply agreement - Investing.com
Radiopharm advances RAD204 trial with expedited phase By Investing.com - Investing.com India
Radiopharm advances RAD204 trial with expedited phase - Investing.com
Radiopharm Theranostics Ltd Adr Stock (RADX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):